Oracle Fusion Middleware is widely deployed; this remote takeover (CVSS 9.9) can compromise middleware and downstream products across enterprises.
CVE-2026-60381
Remote takeover of Oracle Fusion Middleware Service Delivery Platform via T3/IIOP.
Is CVE-2026-60381 being exploited?
Not confirmed. CVE-2026-60381 does not appear in CISA's Known Exploited Vulnerabilities catalog, which records only exploitation that has been observed and reported publicly. That is evidence of absence of a report, not evidence the flaw is unattacked. EPSS currently estimates a 0.43% probability of exploitation in the next 30 days.
How severe is CVE-2026-60381?
CVE-2026-60381 is rated Critical. Severity describes how bad exploitation would be, not how likely it is: pair it with exploitation evidence before deciding what to patch first.
Is there a patch for CVE-2026-60381?
Yes. A fix has been recorded for CVE-2026-60381. The vendor advisory is the authority on the exact fixed version — apply it from there rather than from a summary.
What does CVE-2026-60381 affect?
CVE-2026-60381 affects Oracle Fusion Middleware Service Delivery Platform 12.2.1.4.0, Oracle Fusion Middleware Service Delivery Platform 14.1.2.0.0, Messaging Enabler component (T3/IIOP interfaces). Confirm the exact affected versions against the vendor advisory before deciding you are exposed.
What should I do about CVE-2026-60381?
Apply vendor patch ASAP; if unavailable, block/limit T3/IIOP, isolate hosts, and monitor logs.
Exploitation status reflects CISA's KEV catalog as we last synced it. Check the catalog directly.
Low-privileged remote attacker can take over Service Delivery Platform via T3/IIOP, causing full C/I/A loss and potential lateral compromise.
Immediate action required
- affected12.2.1.4.0
- affected14.1.2.0.0
As published in the CVE Program record. A version outside these ranges is not a statement that it is unaffected — vendors sometimes understate a range, and distribution-backported builds carry upstream numbers that do not reflect what was patched into them.